Your browser doesn't support javascript.
loading
(99m)Tc sestamibi as a prognostic factor of response to first-line therapy and outcome in patients with malignant lymphoma.
Spyridonidis, Trifon J; Matsouka, Panayota; Symeonidis, Argiris; Savvopoulos, Christos; Vassilakos, Pavlos J; Apostolopoulos, Dimitris J.
Affiliation
  • Spyridonidis TJ; From the *Department of Nuclear Medicine, University of Patras Medical School, Patras; †Department of Hematology, University of Larissa Medical School, Larissa; and ‡Department of Hematology, University of Patras Medical School, Patras, Greece.
Clin Nucl Med ; 38(11): 847-54, 2013 Nov.
Article in En | MEDLINE | ID: mdl-24089060
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Technetium Tc 99m Sestamibi / Lymphoma Type of study: Prognostic_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2013 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Technetium Tc 99m Sestamibi / Lymphoma Type of study: Prognostic_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2013 Type: Article